Mirtafoam 15 Tablet contains Mirtazapine 15mg, a tetracyclic antidepressant prescribed for major depressive disorder (MDD), anxiety disorders, and sleep disturbances. It works by enhancing noradrenergic and serotonergic neurotransmission, helping patients achieve better mood, reduced anxiety, and improved sleep quality.
Belonging to the neurology and CNS segment, Mirtafoam 15mg is ideal for patients requiring moderate to high dose antidepressant therapy, and is commonly prescribed by psychiatrists, neurologists, and general physicians.
The tablet promotes enhanced patient adherence due to its tolerable side effect profile and flexible dosing options. Its effectiveness in managing depression and associated symptoms makes it a highly prescribed and sought-after product in hospitals, mental health clinics, and retail pharmacies.
For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Mirtafoam 15 Tablet offers a profitable B2B opportunity in the antidepressant segment, ensuring stable demand and strong market presence across India.